Advertisement
Screener

Orchestra BioMed Holdings, Inc. (OBIO) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Orchestra BioMed Holdings, Inc. Operating Cash Flow

Orchestra BioMed Holdings, Inc. (OBIO) reported Operating Cash Flow of -$41.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10

  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.33M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$22.17M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.27M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$14.55M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$48.96M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$50.56M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$46.13M.
  • Orchestra BioMed Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$29.29M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 4 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 7 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$19.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$41.50M
10-Q · filed 2026-08-10
-$43.77M
derived: sum of 3 quarters · filed 2026-08-10
-$58.32M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31-$22.17M
10-Q · filed 2026-05-12
-$24.44M
derived: sum of 2 quarters · filed 2026-05-12
-$38.99M
derived: sum of 3 quarters · filed 2026-05-12
-$54.52M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31-$2.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$16.82M
derived: sum of 2 quarters · filed 2026-03-12
-$32.35M
derived: sum of 3 quarters · filed 2026-08-10
-$48.96M
10-K · filed 2026-03-12
2025-09-30-$14.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$30.08M
derived: sum of 2 quarters · filed 2026-08-10
-$46.69M
10-Q · filed 2025-11-10
-$60.23M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$15.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$32.14M
10-Q · filed 2026-08-10
-$45.68M
derived: sum of 3 quarters · filed 2026-08-10
-$59.38M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31-$16.62M
10-Q · filed 2026-05-12
-$30.15M
derived: sum of 2 quarters · filed 2026-05-12
-$43.85M
derived: sum of 3 quarters · filed 2026-05-12
-$54.06M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$13.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$27.24M
derived: sum of 2 quarters · filed 2026-03-12
-$37.44M
derived: sum of 3 quarters · filed 2026-03-12
-$50.56M
10-K · filed 2026-03-12
2024-09-30-$13.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$23.91M
derived: sum of 2 quarters · filed 2025-11-10
-$37.02M
10-Q · filed 2025-11-10
-$47.99M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$10.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$23.32M
10-Q · filed 2025-08-12
-$34.29M
derived: sum of 3 quarters · filed 2025-08-12
-$44.58M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$13.11M
10-Q · filed 2025-05-12
-$24.09M
derived: sum of 2 quarters · filed 2025-05-12
-$34.37M
derived: sum of 3 quarters · filed 2025-05-12
-$44.86M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$10.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$21.26M
derived: sum of 2 quarters · filed 2025-03-31
-$31.75M
derived: sum of 3 quarters · filed 2025-03-31
-$46.13M
10-K · filed 2025-03-31
2023-09-30-$10.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$20.77M
derived: sum of 2 quarters · filed 2024-11-12
-$35.15M
10-Q · filed 2024-11-12
-$43.90M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$10.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$24.87M
10-Q · filed 2024-08-12
-$33.62M
derived: sum of 3 quarters · filed 2024-08-12
-$40.87M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$14.38M
10-Q · filed 2024-05-13
-$23.13M
derived: sum of 2 quarters · filed 2024-05-13
-$30.38M
derived: sum of 3 quarters · filed 2024-05-13
-$38.35M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$8.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27
-$16.00M
derived: sum of 2 quarters · filed 2024-03-27
-$23.96M
derived: sum of 3 quarters · filed 2024-03-27
-$29.29M
10-K · filed 2024-03-27
-$1.58M
10-K · filed 2023-01-25
2022-09-30-$7.26M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$15.22M
derived: sum of 2 quarters · filed 2023-11-13
-$20.55M
10-Q · filed 2023-11-13
-$1.02M
10-Q · filed 2022-11-14
-$20.57M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$7.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$13.29M
10-Q · filed 2023-08-10
-$447.76K
10-Q · filed 2022-08-15
-$13.32M
derived: sum of 3 quarters · filed 2023-08-10
-$13.45M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$5.32M
10-Q · filed 2023-05-12
-$335.58K
10-Q · filed 2022-05-13
-$5.35M
derived: sum of 2 quarters · filed 2023-05-12
-$5.48M
derived: sum of 3 quarters · filed 2023-05-12
-$5.52M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$28.84K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-25
-$156.84K
derived: sum of 2 quarters · filed 2023-01-25
-$195.99K
derived: sum of 3 quarters · filed 2023-01-25
-$272.36K
10-K · filed 2023-01-25
2021-09-30-$128.01K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$167.15K
derived: sum of 2 quarters · filed 2022-11-14
-$243.53K
10-Q · filed 2022-11-14
2021-06-30-$39.14K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$115.52K
10-Q · filed 2022-08-15
2021-03-31-$76.37K
10-Q · filed 2022-05-13
2020-12-31-$258.51K
10-K/A · filed 2022-03-31
2020-09-30-$247.52K
10-Q/A · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
SHOULDER INNOVATIONS, INC. (SI)United States$0.355B
Orthofix Medical Inc. (OFIX)$0.373B
Embecta Corp. (EMBC)United States$0.319B2.10
CARLSMED, INC. (CARL)United States$0.405B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Mobia Medical, Inc. (MOBI)United States$0.293B
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Cytosorbents Corp (CTSO)United States$0.274B-1.29
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71